AR042632A1 - Compuestos derivados del acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico como agentes terapeuticos para trastornos en el metabolismo de los lipidos y composiciones farmaceuticas - Google Patents

Compuestos derivados del acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico como agentes terapeuticos para trastornos en el metabolismo de los lipidos y composiciones farmaceuticas

Info

Publication number
AR042632A1
AR042632A1 ARP030104752A ARP030104752A AR042632A1 AR 042632 A1 AR042632 A1 AR 042632A1 AR P030104752 A ARP030104752 A AR P030104752A AR P030104752 A ARP030104752 A AR P030104752A AR 042632 A1 AR042632 A1 AR 042632A1
Authority
AR
Argentina
Prior art keywords
disorders
pharmaceutical compositions
oxoetoxi
etoxipropanoic
lipids
Prior art date
Application number
ARP030104752A
Other languages
English (en)
Inventor
Lanna Li
Christina Olsson
Eva-Lotte Alstermark
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR042632A1 publication Critical patent/AR042632A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Abstract

El enantiómero S de un compuesto de fórmula (1), donde R1 representa cloro, trifluorometilo o trifluorometoxi; R2 representa H o fluoro y R3 representa un grupo alquilo C2-4, así como sales aceptables para uso farmacéutico, solvatos y profármacos del mismo; procesos para preparar dichos compuestos; su utilidad en el tratamiento de trastornos clínicos, por ejemplo de trastornos lipídicos (dislipidemias) relacionados o no relacionados con al resistencia a la insulina; métodos para su uso terapéutico y composiciones farmacéuticas que lo contienen, solo o en combinación con un inhibidor de IBAT.
ARP030104752A 2002-12-21 2003-12-19 Compuestos derivados del acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico como agentes terapeuticos para trastornos en el metabolismo de los lipidos y composiciones farmaceuticas AR042632A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229931.1A GB0229931D0 (en) 2002-12-21 2002-12-21 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR042632A1 true AR042632A1 (es) 2005-06-29

Family

ID=9950253

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104752A AR042632A1 (es) 2002-12-21 2003-12-19 Compuestos derivados del acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico como agentes terapeuticos para trastornos en el metabolismo de los lipidos y composiciones farmaceuticas

Country Status (21)

Country Link
US (1) US7462644B2 (es)
EP (1) EP1572626A1 (es)
JP (2) JP3786945B2 (es)
KR (1) KR20050089065A (es)
CN (1) CN1308291C (es)
AR (1) AR042632A1 (es)
AU (1) AU2003290309B2 (es)
BR (1) BR0317458A (es)
CA (1) CA2508851A1 (es)
CL (1) CL2003002683A1 (es)
CO (1) CO5580820A2 (es)
GB (1) GB0229931D0 (es)
IS (1) IS7946A (es)
MX (1) MXPA05006812A (es)
NO (1) NO20052914L (es)
PL (1) PL377144A1 (es)
RU (1) RU2005117792A (es)
TW (1) TW200508180A (es)
UA (1) UA80729C2 (es)
WO (1) WO2004056748A1 (es)
ZA (1) ZA200504730B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
ATE398615T1 (de) 2002-03-13 2008-07-15 Janssen Pharmaceutica Nv Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase
MXPA04007776A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa.
ES2306858T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas.
OA12790A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
EP1517883B8 (en) 2002-06-20 2008-05-21 AstraZeneca AB Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
EP2287166A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
BRPI0517701A8 (pt) * 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8138198B2 (en) 2005-05-18 2012-03-20 Angibaud Patrick Rene Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
EP1893583B1 (en) 2005-05-31 2012-04-04 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
CN101370789B (zh) 2006-01-19 2012-05-30 詹森药业有限公司 作为组蛋白脱乙酰酶抑制剂的吡啶和嘧啶衍生物
JP5137849B2 (ja) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
DK1981871T3 (da) 2006-01-19 2012-02-13 Janssen Pharmaceutica Nv Heterocyclylalkylderivater som hidtil ukendte inhibitorer af histondeacetylase
DK1981874T3 (da) 2006-01-19 2009-09-28 Janssen Pharmactuica N V Aminophenylderivater som nye inhibitorer af histondeacetylase
WO2007082874A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2007082880A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2009045503A1 (en) 2007-10-05 2009-04-09 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2349255B1 (en) 2008-10-03 2016-03-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
SI2637668T1 (sl) 2010-11-08 2016-11-30 Albiero Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
WO2019245449A1 (en) 2018-06-20 2019-12-26 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266121C (es)
BE489216A (es) 1948-06-05 1900-01-01
US2928840A (en) 1958-11-26 1960-03-15 Us Vitamin Pharm Corp 3-(o-substituted phenyl) oxazolidinediones and process therefor
GB1081471A (en) 1963-09-13 1967-08-31 Stauffer Chemical Co Glycol amide derivatives and use thereof in controlling weed growth
US3244398A (en) 1963-10-28 1966-04-05 Scaramucci Domer Composite seat ball valve
AT307640B (de) 1970-06-18 1973-05-25 Richter Gedeon Vegyeszet Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen
BE792364A (fr) 1971-12-06 1973-06-06 Basf Ag Derives de substitution du sulfonylglycolanilide
DE2349256C2 (de) 1973-10-01 1985-08-01 Basf Ag, 6700 Ludwigshafen 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide
DE2828222A1 (de) 1978-06-28 1980-01-10 Bayer Ag Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide
US4735959A (en) 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
US5216167A (en) 1983-12-30 1993-06-01 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5312924A (en) 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
ATE268750T1 (de) 1997-08-28 2004-06-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6410585B1 (en) 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
EP1026149A4 (en) * 1997-10-02 2004-12-01 Sankyo Co AMIDOCARBONSÄUREDERIVATE
CA2309792A1 (en) 1997-11-12 1999-05-20 William C. Shakespeare Novel signal transduction inhibitors, compositions containing them
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
IL145732A0 (en) 1999-04-06 2002-07-25 Sankyo Co α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO2000061582A1 (fr) 1999-04-08 2000-10-19 Sankyo Company, Limited Derives imidazole condenses substitues
JP2000351777A (ja) * 1999-04-08 2000-12-19 Sankyo Co Ltd 置換縮合イミダゾール誘導体
US6620929B1 (en) 1999-04-14 2003-09-16 University Of British Columbia 1,3-Dipolar cycloadditions to polypyrrolic macrocycles
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP2001261612A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
WO2002044130A1 (fr) 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Dérivés d'acide carboxylique substitués
WO2002044127A1 (fr) 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Dérivés d'acide carboxylique substitué
EP1360172A1 (en) 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
WO2002083616A1 (fr) 2001-04-10 2002-10-24 Sankyo Company, Limited DERIVE D'ACIDE GRAS φomega;-ARYLE α-SUBSTITUE
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
CN1308291C (zh) 2007-04-04
NO20052914D0 (no) 2005-06-15
AU2003290309B2 (en) 2007-01-18
US7462644B2 (en) 2008-12-09
IS7946A (is) 2005-07-19
MXPA05006812A (es) 2005-09-08
AU2003290309A1 (en) 2004-07-14
WO2004056748A1 (en) 2004-07-08
RU2005117792A (ru) 2006-01-27
GB0229931D0 (en) 2003-01-29
CL2003002683A1 (es) 2005-04-08
BR0317458A (pt) 2005-11-16
US20050131068A1 (en) 2005-06-16
UA80729C2 (en) 2007-10-25
JP3786945B2 (ja) 2006-06-21
EP1572626A1 (en) 2005-09-14
TW200508180A (en) 2005-03-01
JP2006045240A (ja) 2006-02-16
CA2508851A1 (en) 2004-07-08
PL377144A1 (pl) 2006-01-23
ZA200504730B (en) 2006-09-27
JP2006511572A (ja) 2006-04-06
CN1753862A (zh) 2006-03-29
KR20050089065A (ko) 2005-09-07
CO5580820A2 (es) 2005-11-30
NO20052914L (no) 2005-07-19

Similar Documents

Publication Publication Date Title
AR042632A1 (es) Compuestos derivados del acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico como agentes terapeuticos para trastornos en el metabolismo de los lipidos y composiciones farmaceuticas
AR038047A1 (es) Agentes terapeuticos
AR047823A1 (es) Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida
ES2527794T3 (es) Procedimiento para preparar compuestos de benzazepina o sus sales
CO5650227A2 (es) Derivados del acido propionico utiles en desordenes lipidicos
ECSP056127A (es) Inhibidores de 3-quinasa de fosfatidil-inositol
CL2004000293A1 (es) Compuestos derivados de dihidrofenantridin-sulfonamidas sustituidas, sus sales; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y su uso en el tratamiento de la diabetes tipo ii, alzheimer, demencia senil, asma, col
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
AR036114A1 (es) Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes
FR2809396B1 (fr) Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
AR038419A1 (es) Derivados de piridina y quinolina
AR068479A1 (es) (carboxilalquilenfenil) feniloxamidas, procedimiento para su preparacion y una coomposicion farmaceutica
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
AR040489A1 (es) Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
AR043430A1 (es) Derivados de diarilcicloalquilo, procesos para su preparacion y su uso como agentes farmaceuticos
UY27786A1 (es) Derivados de isoquinolina.
RU2002130710A (ru) Производное пиридин-1-оксида и способ его преобразования в фармацевтически эффективные соединения
AR074593A1 (es) Benzotiazol amidas para la deteccion del peptido beta amiloide
AR048326A1 (es) Derivados de prolinilo
CU20040161A7 (es) Sales estables de o-ácido acetilsalisílico con amino ácidos básicos ii
AR038046A1 (es) Derivados de acidos 3-fenil-2-arilalquiltiopropionicos moduladores de ppar alfa

Legal Events

Date Code Title Description
FB Suspension of granting procedure